Yelena Janjigian, MD
Hematology & Oncology · New York, NYNPI 1831330034
Payments from drug & device makers
Across 555 payments — averaging $30,379 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$10.2M
- AstraZeneca$3.7M
- E.r. Squibb & Sons, L.L.C.$2.7M
- Boehringer Ingelheim$102K
- Coherus Oncology, Inc.$46K
- Astrazeneca UK Limited$38K
- plus $147K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 369 | $10,153,747 |
| AstraZeneca | 43 | $3,717,470 |
| E.r. Squibb & Sons, L.L.C. | 31 | $2,655,488 |
| Boehringer Ingelheim | 2 | $101,983 |
| Coherus Oncology, Inc. | 1 | $46,091 |
| Astrazeneca UK Limited | 35 | $38,455 |
| Lilly USA, LLC | 1 | $23,890 |
| Daiichi Sankyo Inc. | 26 | $18,590 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $15,283 |
| GSK | 7 | $13,933 |
| Eli Lilly | 2 | $9,550 |
| Sanofi | 3 | $9,208 |
| Beone Medicines USA, Inc. | 4 | $8,355 |
| Pfizer | 4 | $6,173 |
| Sanofi US Services Inc. | 1 | $5,402 |
| Regeneron | 4 | $4,988 |
| Daiichi Sankyo Company LTD | 1 | $4,375 |
| Bayer | 1 | $3,493 |
| G1 Therapeutics, Inc. | 1 | $3,480 |
| Boehringer Ingelheim International GmbH | 2 | $3,330 |
| Eisai Inc. | 1 | $3,140 |
| Daiichi Sankyo Europe GmbH | 1 | $2,740 |
| Beigene USA, Inc. | 3 | $2,408 |
| Kyowa Kirin, Inc. | 1 | $1,963 |
| Novartis | 1 | $1,856 |
| Astellas Pharma US Inc | 1 | $1,725 |
| AbbVie | 1 | $1,303 |
| Seagen Inc. | 1 | $820 |
| Gilead | 3 | $686 |
| Boston Scientific | 1 | $145 |
| Amgen | 1 | $84 |
| Jazz Pharmaceuticals Inc. | 1 | $74 |
How this compares
$16,860,224 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in New York
- Vicky MakkerNew York$27.1M
- Alison MoskowitzNew York$22.7M
- Ajai ChariNew York$22.4M
- Alexander LesokhinNew York$11.9M
- John MascarenhasNew York$11.8M
- Maria PalombaNew York$11.6M
- Scott TagawaNew York$10.3M
- Mohammad Abdul HayNew York$9.9M
- Joshua SabariNew York$9.7M
- Sherry ShenNew York$9.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.